error: Content is protected !!
STADA puts Serbia-based Hemofarm at center of its SEE region - Serbia Business

STADA puts Serbia-based Hemofarm at center of its SEE region

, News

A strategic reorganization of the German STADA Group has resulted in the setting up of a Southeast Europe group, which will in the future be led by Hemofarm.

Hemofarm CEO Ronald Seeliger announced this in an interview for the FoNet news agency, stressing that this was good news for the pharmaceutical company based in Vrsac, northeast Serbia, but also for the country itself.

Seeliger explained that the German group that includes Hemofarm decided in favor of strategic changes to improve efficiency and operations in all regions and
stressed that the change involves his appointment as STADA’s vice president for Southeast Europe (SEE).

So far STADA has been organized into three zones, Western Europe, Germany and the East, but due to the changes in the global market this structure was no longer viable, he said, adding that this was the reason why the decision was made to distribute regional responsibilities differently.

That decision means there will be six regional zones, including Hemofarm that is in charge of Southeast Europe, said Seeliger, and recalled that the company in Vrsac has in recent years developed a very successful business.

STADA’s shareholders therefore very clearly noticed that Hemofarm should conduct the business in Southeast Europe, covering the territory of Hungary, Slovenia, Croatia, Bosnia-Herzegovina, Serbia, Albania, Bulgaria and Romania.

“We will be the main company for this area, and I will be its general manager,” said Seeliger and explained that this is a territory with “10 or 11 countries” and about 3,500 employees.

According to Seeliger, this change means that the production portfolio of Hemofarm will be harmonized with the markets of these countries, taking into account their specific differences.

This, however, means that good products of Hemofarm, until now available in Serbia, Bosnia and Macedonia, will in the future be available across Southeast Europe, said Seeliger, who is proud of his team “because it, with the good work, deserved to be entrusted with operations in the region.”

“Now we can have better marketing and promotional access to regional markets,” announced Seeliger, adding that for him personally, this change will not be huge, as he will continued to do his job as before – but noted he was “happy that he will also work with colleagues in the region.”

“We have already met several times and we have had contacts with the governments in these countries,” he said, and predicted that this change would “certainly strengthen the position of Hemofarm.”

While many large companies in this area have either disappeared or reduced their presence of, Hemofarm remained, but will now in a bigger market be able to more effectively resolve the difficulties and balance the business.

“I am proud that Serbian medicines produced in Hemofarm’s plants will be available to citizens in all countries of the region, which is good news for Serbia,” said Seeliger.

The flag of a traditional old Serbian company will fly across the region, said Seeliger, who has also discussed the new position of Hemofarm with representatives of the government of Serbia.

“They immediately noted the new possibilities and perspectives, not only because of Hemofarm’s link to regional markets, but because of my role as president of the German-Serbian Chamber of Commerce, which will be strengthened,” he said.

All this will contribute to connecting local industries and local markets, concluded Seeliger.